The negotiations with drugmakers are projected to save older adults $1.5 billion in out-of-pocket costs when the new prices go into effect in 2026.

The negotiations with drugmakers are projected to save older adults $1.5 billion in out-of-pocket costs when the new prices go into effect in 2026.

The Biden administration said Thursday that it had reached an agreement with drugmakers to lower prices on the 10 costliest prescription drugs under Medicare.

It’s part of the federal government’s first-ever drug pricing negotiations, a cost reduction it claims could help ease the financial burden on the estimated 1 in 7 older adults in the U.S. struggling to pay for their medications.

    • henfredemars@infosec.pubEnglish
      12·
      4 months ago

      We’re paying more than it should cost to simply run our own national healthcare system. It’s ridiculous. Somebody’s getting really, really rich and it ain’t us.

  • ShinkanTrain@lemmy.mlEnglish
    162·
    4 months ago

    I checked and 7 of those 10 meds are free here, the other 3 are under $30 for a monthly refill.

    Having healthcare is nice, y’all USAians should try it sometime.

    • HeyJoe@lemmy.world
      4·
      4 months ago

      I just saw a news segment about this and the woman used as an example was spending 22k a year on one of these medications for the past 8 years and to make ends meet they have been selling off things like their car and mess with their mortgage to take out more money. What a way to live in the US… and this is just 1 of the many ways this country tries to cripple you for life if you’re not lucky.

  • WizEnglish
    12·
    4 months ago

    Thanks, Biden!

    Thanks, Harris!

  • slacktoid@lemmy.mlEnglish
    2·
    4 months ago

    Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer: $231 negotiated price, down from $521 list price.

    Xarelto, a blood thinner from Johnson & Johnson: $197 negotiated price, down from $517 list price.

    Januvia, a diabetes drug from Merck: $113 negotiated price, down from $527 list price.

    Jardiance, a diabetes drug from Boehringer Ingelheim and Eli Lilly: $197 negotiated price, down from $573 list price.

    Enbrel, a rheumatoid arthritis drug from Amgen: $2,355 negotiated price, down from $7,106 list price.

    Imbruvica, a drug for blood cancers from AbbVie and Johnson & Johnson: $9,319 negotiated price, down from $14,934 list price.

    Farxiga, a drug for diabetes, heart failure and chronic kidney disease from AstraZeneca: $178 negotiated price, down from $556 list price.

    Entresto, a heart failure drug from Novartis: $295 negotiated price, down from $628 list price.

    Stelara, a drug for psoriasis and Crohn’s disease from J&J: $4,695 negotiated price, down from $13,836 list price.

    Fiasp and NovoLog, diabetes drugs from Novo Nordisk: $119 negotiated price, down from $495 list price.

    Still a shitshow tho.

  • Someonelol@lemmy.dbzer0.comEnglish
    1·
    4 months ago

    I was thinking the prices for most of these drugs would’ve been dropped to the high double digits. It’s a step in the right direction at least.

  • Media Bias Fact Checker@lemmy.worldB
    510·
    4 months ago
    NBC News - News Source Context (Click to view Full Report)

    Information for NBC News:

    MBFC: Left-Center - Credibility: High - Factual Reporting: High - United States of America
    Wikipedia about this source

    Search topics on Ground.News

    https://www.nbcnews.com/health/health-care/medicare-names-first-10-drugs-price-negotiation-government-rcna101166
    https://www.nbcnews.com/health/health-news/medicare-cost-lower-medication-diabetes-blood-thinners-rcna166385
    https://www.nbcnews.com/health/health-news/medicare-drug-price-negotiations-start-rcna136181

    Media Bias Fact Check | bot support